Dr. Carson Discusses Mogamulizumab as Potential Treatment for CTCL
In Partnership With:
Kenneth R. Carson, MD, assistant professor, Division of Oncology, Washington University, discusses mogamulizumab as a potential treatment for patients with relapsed or refractory cutaneous T cell lymphoma (CTCL).
Kenneth R. Carson, MD, assistant professor, Division of Oncology, Washington University, discusses mogamulizumab as a potential treatment for patients with relapsed or refractory cutaneous T cell lymphoma (CTCL).
Carson says mogamulizumab is a new anti-CCR4 monoclonal antibody. CCR4 is expressed on most cutaneous lymphoma T cells. This antibody, Carson says, is glycoengineered to enhance antibody-dependent cellular cytotoxicity.
Preliminary results from phase II studies have suggested that single-agent mogamulizumab enhances disease response in patients who have relapsed or refractory CTCL. The antibody is also well tolerated, Carson says.
